How to Read Peptide Research: In Vitro, Animal and Human Evidence

In plain English

Scientists test peptides in steps. First come experiments on cells in a dish (in vitro, Latin for “in glass”). Next come studies in animals such as rats and mice (preclinical studies). Last come studies in people, from small early studies up to large randomised trials, where people are assigned to groups by chance ^[4].

Each step answers a different question. A cell study can show that a molecule reaches a target. It cannot show what happens in a whole body. Animal results often fail to carry over to people. In one large review, only 5% of treatments tested in animals went on to be approved for human use ^[1].

What a reader should ask about any claim:

• Was it tested in cells, animals or people?
• Was there a comparison group, chosen by chance?
• Has another, independent team found the same thing ^[8]?

Every compound article in this library shows an evidence level: how far up these steps the research has reached.

The evidence levels we use

The table below explains each label and what that kind of study can and cannot show.

The evidence pyramid, and its limits

The classic “evidence pyramid” ranks study designs by how well they protect against bias. Basic science and case series sit at the bottom, case–control and cohort studies in the middle, then randomised controlled trials, with systematic reviews and meta-analyses at the top ^[4].

A 2016 proposal revised this picture in two ways ^[4]:

• The lines between levels are wavy. A well-designed study lower on the pyramid can be more trustworthy than a poorly designed one higher up.
• Systematic reviews are taken out of the pyramid. They are treated as a lens for appraising and combining evidence, rather than as a level of their own.

For peptides, this means a systematic review of 35 rat studies is still preclinical evidence.

In vitro studies: useful, but far from the body

In vitro work (“in glass”) is where most mechanisms are first described. A cell experiment can show that a peptide activates a receptor, switches on a signalling pathway or changes gene expression. For the basics of what peptides are, see What Are Peptides?; for unfamiliar terms, see the Peptide Glossary.

Questions to ask:

• Which cells? Immortalised cell lines, primary cells and tissue explants can behave differently.
• What concentration? Cells may be exposed to concentrations that are never reached in a living animal.
• What controls? Was there a vehicle control and, ideally, a known reference compound?
• What was measured? A change in a marker (such as gene expression) is not the same as a change in tissue structure or function.

Animal studies: the translation problem

Animal studies add a whole living system, with absorption, metabolism and clearance. But they have well-documented limits as predictors of human outcomes ^{[2, 3]}.

How often do animal findings translate?

Why animal findings fail to translate

A 2010 analysis grouped the reasons into two kinds ^[2]:

Internal validity (was the study itself sound?)

• Many animal studies did not report randomisation or blinded outcome assessment.
• A priori sample size calculations were reported in only 0–3% of the animal studies reviewed.
• In animal studies of emergency-medicine interventions, the odds of a positive finding were more than three times higher when randomisation or blinding was not reported.
• Publication bias, where neutral findings go unpublished, inflates apparent effects.

External validity (does the model resemble the human situation?)

• Animals are often young and otherwise healthy, while the human condition may mainly occur in older people with other illnesses.
• The timing and amount of treatment used in animals may not match what is achievable in humans.
• Outcome measures in animals may differ from those that matter clinically.

Reporting standards such as the ARRIVE 2.0 guidelines aim to improve this. Their “Essential 10” checklist sets the minimum information an animal study should report so that others can judge its rigour and reproduce it ^[5].

Human studies: how designs differ

Human data range from single case reports to large randomised trials.

• Case reports and case series describe what happened to one or a few people. With no comparison group, they cannot separate an effect of the compound from chance or the natural course of a condition.
• Retrospective chart reviews look back at records. They are prone to selection bias and inconsistent measurement.
• Pilot and phase 1 studies are small and mainly assess tolerability and pharmacokinetics.
• Randomised controlled trials (RCTs) allocate participants by chance to the compound or a control. They are the strongest single-study design for cause and effect.

Even RCTs can mislead, especially small ones. An analysis of 45 highly cited clinical studies that claimed an intervention was effective found that 16% were later contradicted and another 16% had reported stronger effects than later studies. Only 44% were replicated. Non-randomised studies were contradicted or overstated more often than randomised trials ^[6].

Replication by independent groups

A single study, however striking, is more convincing once an independent group has repeated it.

• Small studies are fragile. Findings are less likely to be true when studies are small, effect sizes are small, designs and analyses are flexible, and many teams chase statistical significance ^[7].
• Replication attempts often shrink effects. A large project repeated 50 experiments from 23 high-impact preclinical papers. For positive effects, the median effect size in the replications was 85% smaller than in the originals, and 40% of positive effects were successfully replicated by most of the criteria used ^[8].
• A failed replication is not a disproof. The same project stressed that a failure to replicate does not disconfirm a finding, but it does mean more investigation is needed ^[8].

For peptide research, check whether findings come from several independent laboratories or mostly from one group.

A checklist for reading a peptide study

1. Which molecule? Confirm the exact peptide, its sequence and its source. Was its identity and purity verified? (See How to Read a Peptide Certificate of Analysis.)
2. Which model? Cells, which animal species, or people?
3. What was measured? A biomarker, a tissue change or a clinical outcome?
4. Was there a control group? And was allocation randomised?
5. Was outcome assessment blinded?
6. How large was the study? Was the sample size calculated in advance?
7. Who did it? Is the finding replicated by independent groups?
8. Was it registered in advance? For human trials, check a registry such as ClinicalTrials.gov ^[9].
9. Who funded it, and are conflicts declared?
10. What do systematic reviews say? And how strong are the studies they include?

What this means in Australia

The evidence level of a compound and its legal status in Australia are separate questions.

• Approved means on the ARTG. A medicine approved for supply in Australia is entered on the Australian Register of Therapeutic Goods (ARTG), which can be searched online ^[11]. Strong evidence in published studies does not by itself put a product on the ARTG.
• Unapproved products have not been assessed. The TGA states that unapproved peptide products have not been assessed by the TGA for safety, quality or effectiveness. It also states that a “research use only” disclaimer does not make supply lawful, and does not change regulatory status, permit importation, or remove advertising or supply obligations ^[12]. In June 2026 the TGA added unapproved peptide products to its compliance priorities ^[13].
• Scheduling is compound by compound. Some research peptides are named in the current Poisons Standard (October 2026); for example, BPC-157 and TB-500 are Schedule 4 (prescription-only) and Appendix D, clause 5 (possessing them without authority is illegal) ^[14]. Each compound article in this library states its own status. See Are Peptides Legal in Australia?.

This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.

Frequently asked questions

What is the difference between in vitro and in vivo?

In vitro studies are done in cells or tissue outside a living organism. In vivo studies are done in a living animal or person. In vivo work captures absorption, metabolism and clearance, which in vitro work cannot.

Can animal studies predict effects in humans?

Sometimes, but not reliably. In one umbrella review, only 5% of animal-tested therapies reached regulatory approval for human use, although positive animal and human findings agreed 86% of the time where both were available ^[1].

What is the strongest type of evidence?

Well-conducted randomised controlled trials, and systematic reviews of them. Study quality matters as much as study type ^[4].

Why does replication matter?

Single studies, especially small ones, can overstate effects. Independent replications often find smaller effects than the original reports ^[6–8].

Where can I find peptide studies and trials?

PubMed indexes peer-reviewed studies ^[10], and ClinicalTrials.gov lists registered human trials and their status ^[9].

References

1. Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biol. 2024;22(6):e3002667. doi:10.1371/journal.pbio.3002667. PMID: 38870090
2. van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245. doi:10.1371/journal.pmed.1000245. PMID: 20361020
3. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334(7586):197. doi:10.1136/bmj.39048.407928.BE. PMID: 17175568
4. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21(4):125–127. doi:10.1136/ebmed-2016-110401. PMID: 27339128
5. Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410. PMID: 32663219
6. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218–228. doi:10.1001/jama.294.2.218. PMID: 16014596
7. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124. doi:10.1371/journal.pmed.0020124. PMID: 16060722
8. Errington TM, Mathur M, Soderberg CK, et al. Investigating the replicability of preclinical cancer biology. eLife. 2021;10:e71601. doi:10.7554/eLife.71601. PMID: 34874005
9. ClinicalTrials.gov. US National Library of Medicine. clinicaltrials.gov. Accessed 11 October 2026.
10. PubMed. US National Library of Medicine. pubmed.ncbi.nlm.nih.gov. Accessed 11 October 2026.
11. Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG) search. tga.gov.au/resources/artg. Accessed 11 October 2026.
12. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 11 October 2026.
13. Therapeutic Goods Administration. TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response. Media release, 10 June 2026. tga.gov.au. Accessed 11 October 2026.
14. Commonwealth of Australia. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). legislation.gov.au/F2026L01327/latest/text. Accessed 11 October 2026.

Important information and disclaimer

General information only. This article is published for general educational and informational purposes. It summarises published scientific literature and public regulatory information as at the “last reviewed” date shown above. It is not medical, health, pharmaceutical, veterinary or legal advice, and it must not be relied on as a substitute for advice from a qualified professional about your circumstances.

Not for human or animal use. Nothing in this article recommends, endorses or describes the use of any substance in humans or animals. Findings from cell, animal or early human studies cannot be assumed to apply to people. The compounds discussed have not been evaluated by the Therapeutic Goods Administration (TGA) for safety, quality or efficacy unless the article expressly states otherwise. Any research materials offered by Iconic Peptides are supplied solely for in vitro and laboratory research.

No therapeutic claims. Iconic Peptides makes no claim that any product treats, cures, prevents, alleviates or diagnoses any disease, condition or symptom. References to published studies, clinical trials or medicines approved by regulators are factual descriptions of the scientific and regulatory record. They are not representations about any product we supply.

Regulatory status. Many peptides are scheduled substances under the Poisons Standard. Some are prescription-only (Schedule 4), and some may not be possessed without authority (Appendix D). The TGA has stated that a “research use only” label does not make supply lawful, change a product’s regulatory status, or remove advertising or supply obligations. State and territory laws may also apply. You are responsible for knowing and complying with all laws that apply to you. Regulatory information in this article may change after the review date.

Accuracy and third-party sources. We take care to cite and verify every source, but we do not warrant that this article is complete, current or error-free. Citing a study or organisation does not mean that its authors or that organisation endorse Iconic Peptides.

Limitation of liability. To the maximum extent permitted by law, Iconic Peptides, its owners, employees and contributors exclude all liability for any loss, damage, injury or expense, whether direct, indirect or consequential, arising from use of or reliance on this article or any misuse of any product. Nothing in this disclaimer excludes, restricts or modifies any right or remedy under the Australian Consumer Law that cannot lawfully be excluded.

Age restriction. This website is intended for adults aged 18 and over.